Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology
Autoimmune gastrointestinal dysmotility (AGID), an idiopathic or paraneoplastic phenomenon, is a clinical form of limited autoimmune dysautonomia. The symptoms of AGID and gastrointestinal manifestations in patients with autoimmune rheumatic diseases are overlapping. Antineuronal autoantibodies are...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-04-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/25785826.2020.1797319 |
| _version_ | 1819070819996794880 |
|---|---|
| author | Shunya Nakane Akihiro Mukaino Eikichi Ihara Yoshihiro Ogawa |
| author_facet | Shunya Nakane Akihiro Mukaino Eikichi Ihara Yoshihiro Ogawa |
| author_sort | Shunya Nakane |
| collection | DOAJ |
| description | Autoimmune gastrointestinal dysmotility (AGID), an idiopathic or paraneoplastic phenomenon, is a clinical form of limited autoimmune dysautonomia. The symptoms of AGID and gastrointestinal manifestations in patients with autoimmune rheumatic diseases are overlapping. Antineuronal autoantibodies are often detected in patients with AGID. Autoantibodies play a key role in GI dysmotility; however, whether they cause neuronal destruction is unknown. Hence, the connection between the presence of these autoantibodies and the specific interference in synaptic transmission in the plexus ganglia of the enteric nervous system has to be determined. The treatment options for AGID are not well-defined. However, theoretically, immunomodulatory therapies have been shown to be effective and are therefore used as the first line of treatment. Nonetheless, diverse combined immunomodulatory therapies should be considered for intractable cases of AGID. We recommend comprehensive autoimmune evaluation and cancer screening for clinical diagnosis of AGID. Univocal diagnostic criteria, treatment protocols, and outcome definitions for AGID are required for prompt diagnosis and treatment and appropriate management of immunotherapy, which will circumvent the need for surgeries and improve patient outcome. In conclusion, AGID, a disease at the interface of clinical immunology and neurogastroenterology, requires further investigations and warrants cooperation among specialists, especially clinical immunologists, gastroenterologists, and neurologists. |
| first_indexed | 2024-12-21T17:12:00Z |
| format | Article |
| id | doaj.art-498075200f74463f86480a0ac4855272 |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-12-21T17:12:00Z |
| publishDate | 2021-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-498075200f74463f86480a0ac48552722022-12-21T18:56:22ZengTaylor & Francis GroupImmunological Medicine2578-58262021-04-01442748510.1080/25785826.2020.17973191797319Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterologyShunya Nakane0Akihiro Mukaino1Eikichi Ihara2Yoshihiro Ogawa3Department of Molecular Neurology and Therapeutics, Kumamoto University HospitalDepartment of Molecular Neurology and Therapeutics, Kumamoto University HospitalDepartment of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Kyushu UniversityDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu UniversityAutoimmune gastrointestinal dysmotility (AGID), an idiopathic or paraneoplastic phenomenon, is a clinical form of limited autoimmune dysautonomia. The symptoms of AGID and gastrointestinal manifestations in patients with autoimmune rheumatic diseases are overlapping. Antineuronal autoantibodies are often detected in patients with AGID. Autoantibodies play a key role in GI dysmotility; however, whether they cause neuronal destruction is unknown. Hence, the connection between the presence of these autoantibodies and the specific interference in synaptic transmission in the plexus ganglia of the enteric nervous system has to be determined. The treatment options for AGID are not well-defined. However, theoretically, immunomodulatory therapies have been shown to be effective and are therefore used as the first line of treatment. Nonetheless, diverse combined immunomodulatory therapies should be considered for intractable cases of AGID. We recommend comprehensive autoimmune evaluation and cancer screening for clinical diagnosis of AGID. Univocal diagnostic criteria, treatment protocols, and outcome definitions for AGID are required for prompt diagnosis and treatment and appropriate management of immunotherapy, which will circumvent the need for surgeries and improve patient outcome. In conclusion, AGID, a disease at the interface of clinical immunology and neurogastroenterology, requires further investigations and warrants cooperation among specialists, especially clinical immunologists, gastroenterologists, and neurologists.http://dx.doi.org/10.1080/25785826.2020.1797319autoimmune gastrointestinal dysmotilityautoantibodyganglionic acetylcholine receptorautoimmune autonomic ganglionopathyautoimmune rheumatic diseases |
| spellingShingle | Shunya Nakane Akihiro Mukaino Eikichi Ihara Yoshihiro Ogawa Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology Immunological Medicine autoimmune gastrointestinal dysmotility autoantibody ganglionic acetylcholine receptor autoimmune autonomic ganglionopathy autoimmune rheumatic diseases |
| title | Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology |
| title_full | Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology |
| title_fullStr | Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology |
| title_full_unstemmed | Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology |
| title_short | Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology |
| title_sort | autoimmune gastrointestinal dysmotility the interface between clinical immunology and neurogastroenterology |
| topic | autoimmune gastrointestinal dysmotility autoantibody ganglionic acetylcholine receptor autoimmune autonomic ganglionopathy autoimmune rheumatic diseases |
| url | http://dx.doi.org/10.1080/25785826.2020.1797319 |
| work_keys_str_mv | AT shunyanakane autoimmunegastrointestinaldysmotilitytheinterfacebetweenclinicalimmunologyandneurogastroenterology AT akihiromukaino autoimmunegastrointestinaldysmotilitytheinterfacebetweenclinicalimmunologyandneurogastroenterology AT eikichiihara autoimmunegastrointestinaldysmotilitytheinterfacebetweenclinicalimmunologyandneurogastroenterology AT yoshihiroogawa autoimmunegastrointestinaldysmotilitytheinterfacebetweenclinicalimmunologyandneurogastroenterology |